OSAKA, Japan and SAN DIEGO,
The Phase 2a study is a randomized controlled trial assessing the efficacy and safety of intravitreal injections of DE-122 in combination with Lucentis® (ranibizumab) compared to Lucentis monotherapy in patients with wet AMD. DE-122 is the ophthalmic formulation of TRACON’s proprietary anti-endoglin antibody, TRC105. The initiation of the Phase 2a study triggers a
“Santen is a global pharmaceutical company specialized in the field of ophthalmology, and we are committed to delivering novel medicines for the treatment of high unmet need ophthalmic conditions on a global basis. With limited treatment options available for retinal disease, including wet AMD, Santen is pleased at the development progress of DE-122, which we hope will allow Santen to contribute in new ways to improving the quality of life of patients suffering from retinal disease such as wet AMD,” said Akira Kurokawa, President and CEO of Santen.
“The initiation of the trial represents an important opportunity to expand the scope of our endoglin antibodies to areas of significant unmet medical need beyond oncology,” said Charles Theuer, M.D., Ph.D., President and CEO of TRACON. “Data generated to date suggest the novel mechanism of action of DE-122 has the potential to combine effectively with approved VEGF inhibitors, the current standard of care, in patients with wet AMD.”
DE-122 is the ophthalmic formulation of TRACON’s proprietary anti-endoglin antibody, TRC105, and is being studied in Santen’s Phase 1/2 study in the U.S. to investigate the safety of single DE-122 intravitreal injection for the treatment of refractory wet AMD.
TRC105 is a novel, clinical stage antibody to endoglin, a protein overexpressed on proliferating endothelial cells that is essential for angiogenesis, the process of new blood vessel formation. TRC105 is currently being studied in one Phase 3 clinical trial and multiple Phase 2 clinical trials sponsored by both TRACON and the
About Wet AMD
Wet AMD is the leading cause of blindness in the elderly in the world and is caused by excessive growth and leakage of blood vessels at the back of the eye that leads to a chronic and often rapid loss of vision. Existing therapies for the disease are limited including treatment targeting the VEGF pathway.
As a specialty company dedicated to the ophthalmic field, Santen carries out research, development, marketing and sales of pharmaceuticals. Santen is the market leader in Japan for prescription ophthalmic pharmaceuticals and sells products in approximately 60 countries. As a leading company in the field of ophthalmology, Santen aims to contribute to society by supplying valuable products and services to satisfy unmet medical needs. For more details, please see Santen’s website (www.santen.com).
TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen; TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma; and TRC253, a small molecule that is being developed for the treatment of prostate cancer. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
Santen Forward-looking Statements
Information provided in this press release contains so-called “Forward-looking Statements.” The realizations of these forecasts are subject to risk and uncertainty from various sources. Therefore, please note that the actual results may differ significantly from the forecasts. Business performance and financial condition are subject to the effects of change in regulations made by the governments of Japan and other nations concerning medical insurance, drug pricing and other systems, and to fluctuations in market variables such as interest rates and foreign exchange rates.
TRACON Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding TRACON’s receipt of the milestone payment associated with Santen’s initiation of the Phase 2a clinical study and the potential of DE-122 as a treatment for wet AMD. Forward-looking statements speak only as of the date of this press release and TRACON does not undertake any obligation to update or revise these statements, except as may be required by law. These forward-looking statements are based on management's expectations and assumptions as of the date of this press release and actual results may differ materially from those in these forward-looking statements as a result of various factors. These factors include, but are not limited to, whether TRACON’s collaboration with Santen will continue and both parties will continue to perform their obligations under the license agreement, whether Santen will continue clinical trials of DE-122 and risks associated with the development of investigational drug products. For a further description of these and other risks facing TRACON, please see the risk factors described in TRACON’s filings with the
Contacts: TRACON: Casey Logan Chief Business Officer +1-858-550-0780 ext. 236 firstname.lastname@example.org Santen: Christopher Hohman
Corporate Communications Group+81-6-4802-9360 email@example.com